UroGen Pharma (URGN) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.28

Estimate

-$0.26

Surprise

-5.7%

Revenue (period 2026-06-30)

$72.5M

Score at report (before → after)

5.7 → 5.8/10

Revenue source: xbrl.

UroGen Pharma (URGN) reported a wider loss than forecast — adjusted EPS of -$0.28 against the -$0.26 estimate (a 5.7% shortfall). TrendMatrix's engine moved from Hold (5.7/10) to Buy (Wait) at 5.8/10 after the report — the engine's score rose despite the miss.

TrendMatrix currently rates URGN Sell at 6.2/10.

1 of the last 4 quarters beat the estimate; this quarter's -5.7% surprise compares with a -1.9% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$41.43

Price target

$52.20

Stop

$38.53

Upside to target

+26.0%

Reward-to-risk

3.1:1

Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.03B

P/E (fwd)

14.8

52-week range

$15.86–$50.81

Off 52-week high

18.5%

RSI (14)

37

Volume vs avg

0.99×

Score today

6.2/10